SCHEMBL21403547

SCHEMBL21403547

Cc1nc(O)c2ncc(Br)cc2n1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
NQO2 P16083 4/20 0.35
DYRK1A Q13627 3/20 0.34
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
PRNP P04156 1/20 0.32
HPGD P15428 1/20 0.32
NOD2 Q9HC29 1/20 0.32
KMT2A Q03164 1/20 0.31
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
PTGES O14684 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2727243 0.81 DYRK1A (0.36) HTTSMN1; SMN2NPSR1ALDH1A1MAPT
SCHEMBL14895067 0.79 DYRK1A (0.39) HTTSMN1; SMN2NPSR1ALDH1A1MAPT
SCHEMBL28963467 0.75 PARP1 (0.38)
SCHEMBL21403557 0.75 DYRK1A (0.32) NQO2DYRK1A
SCHEMBL31354048 0.75 HTT (0.33) HTTDYRK1AKMT2APTGES
SCHEMBL21403775 0.74 HTT (0.41) HTTSMN1; SMN2NPSR1ALDH1A1MAPT
SCHEMBL30059116 0.74 HTT (0.41) HTTSMN1; SMN2NPSR1ALDH1A1MAPT
SCHEMBL14895071 0.73 DYRK1A (0.42) ALDH1A1DYRK1AKDM4E
SCHEMBL7427955 0.73 MPO (0.46) HTTALDH1A1NQO2KMT2A
SCHEMBL4978434 0.72 DYRK1A (0.37) HTTSMN1; SMN2NPSR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566675-A2 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2025-06-11 EP disclosed
US-20250171443-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2025-05-29 US disclosed
CN-119613400-A Heterocyclic compounds as immunomodulators 因赛特公司 2025-03-14 CN disclosed
US-12247026-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2025-03-11 US disclosed
EP-4212529-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2025-01-29 EP disclosed
CN-112135824-B Heterocyclic compounds as immunomodulators 因赛特公司 2024-11-05 CN disclosed
EP-4212529-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2023-07-19 EP disclosed
EP-3774791-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2022-12-21 EP disclosed
US-20210380584-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2021-12-09 US disclosed
US-11124511-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2021-09-21 US disclosed
EP-3774791-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2021-02-17 EP disclosed
CN-112135824-A Heterocyclic compounds as immunomodulators 因赛特公司 2020-12-25 CN disclosed
US-20200255424-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2020-08-13 US disclosed
US-10669271-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2020-06-02 US disclosed
WO-2019191707-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2019-10-03 WO disclosed
US-20190300524-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300524-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885
US-10669271-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885
US-20200255424-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885
US-20210380584-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885
US-11124511-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885
US-12247026-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885
US-20250171443-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS HTT 3758/4885SMN1; SMN2 4119/4885NPSR1 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.